Have any questions? 706-721-6582 or cts@augusta.edu
- Assessment of Immune Cell function of kidney and kidney pancreas transplant recipients. A marker of strength of immunosuppression resulting from maintenance therapy after transplant: A Single Center Experience
Clinical Trial
Assessment of Immune Cell function of kidney and kidney pancreas transplant recipients. A marker of strength of immunosuppression resulting from maintenance therapy after transplant: A Single Center Experience
In this study we will investigate the immune cell function of transplant recipients. This test measures the concentration of Adensoine-tri-phosphate (ATP) from circulating CD4 cells as a measure of immune cell function in the transplant recipients. The test has three ranges< 225 ng/ml. Low immune cell response, 226-524 ng/ml. Moderate Immune cell response and >524 ng/ml. Strong Immune cell response. We hypothesize that routine screening of immune function assessment can be effective in undertstanding the level of immunosuppression and thus in the prevention of allograft injury caused by rejection or infections. Findings from this study may lead to future larger studies. This is an observational study to identify if Immuknow test can help to assess the strength of the immune system. Patient will continue to recieve standard of care by their Physicians.
Eligibility Criteria
- Inclusion Criteria: Deceased and Living donor kidney and kidney pancreas transplant recipients 18 years of age and older, Patients transplanted on/ after 01 August 2021 at Augusta University Medical Center, Exclusion Criteria: Pediatric kidney transplant recipients, Patient with inadequate data, Pregnancy: Leads to false positive test